Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CAMX
#10606
Cambiar Aggressive Value ETF
31.480
0
USD
-1.66%
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.66%
Monthly Change
-3.41%
6 month change
-3.41%
Year Change
-3.41%
Previous Close
32.009
8
Open
31.440
0
Bid
Ask
Low
31.440
0
High
31.480
0
Volume
2
Markets
US Stock Market
Financial
CAMX
Open full chart
Top holdings
Market Value
Shares
Weight %
ELEVANCE HEALTH, INC.
2.97 M
9 350.00
5.03%
Amrize AG
2.59 M
49.87 K
4.38%
UNP
UNION PACIFIC CORPORATION
2.56 M
11.64 K
4.35%
UBER
UBER TECHNOLOGIES, INC.
2.50 M
25.86 K
4.23%
MEDTRONIC PUBLIC LIMITED COMPANY
2.34 M
25.82 K
3.97%
DAL
DELTA AIR LINES, INC.
2.23 M
38.80 K
3.77%
CVX
CHEVRON CORPORATION
2.17 M
13.78 K
3.68%
TARGET CORPORATION
2.12 M
22.88 K
3.60%
Nintendo Co., Ltd.
2.11 M
98.64 K
3.58%
TXN
TEXAS INSTRUMENTS INCORPORATED
2.06 M
12.73 K
3.48%
HON
HONEYWELL INTERNATIONAL INCORPORATION
2.04 M
10.15 K
3.46%
LH
LABCORP HOLDINGS INC.
2.03 M
7 974.00
3.43%
BMY
BRISTOL-MYERS SQUIBB COMPANY
2.02 M
43.84 K
3.42%
GOOGL
ALPHABET INC.
2.01 M
7 162.00
3.41%
AIRBNB, INC.
1.97 M
15.59 K
3.34%
SHIMANO INC.
1.93 M
185.06 K
3.28%
ALIGN TECHNOLOGY, INC.
1.92 M
13.93 K
3.25%
NXP Semiconductors N.V.
1.86 M
8 878.00
3.15%
Airbus SE
1.84 M
30.04 K
3.13%
MAS
MASCO CORPORATION
1.83 M
28.30 K
3.11%
News
Camurus reports Q4 revenue miss, lowers 2026 outlook
FDA accepts Camurus’ resubmission for acromegaly treatment Oclaiz
Camurus Q3 2025 slides: Revenue up 18% but stock dips on lowered guidance
Camurus cuts 2025 revenue forecast as Buvidal sales miss estimates
Camurus Q2 2025 slides reveal 52% revenue surge and key regulatory milestones
Earnings call transcript: Camurus AB Q2 2025 earnings beat expectations
Camurus Q2 2025 slides: Record revenue and profit amid product portfolio expansion
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal ® incretins
Camurus Q1 2025 slides: record profitability despite market challenges
Camurus stock falls on 1Q revenue miss